PEPGEN INC. Noncash Merger Related Costs
PEPGEN INC. (PEPG) reported Noncash Merger Related Costs of $0 for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NoncashMergerRelatedCosts · last filed 2026-05-12
- PEPGEN INC. noncash merger related costs for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- PEPGEN INC. noncash merger related costs for the quarter ending 2025-09-30 was $0.00.
- PEPGEN INC. noncash merger related costs for the quarter ending 2025-06-30 was -$11.00K.
- PEPGEN INC. noncash merger related costs for the quarter ending 2025-03-31 was $11.00K, a 45.00% decline year-over-year.
- PEPGEN INC. noncash merger related costs for fiscal 2024 was $70.00K.
- PEPGEN INC. noncash merger related costs for fiscal 2022 was $134.00K.
| Period end | Noncash Merger Related Costs 3 month | Noncash Merger Related Costs 6 month | Noncash Merger Related Costs 9 month | Noncash Merger Related Costs 12 month |
|---|---|---|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$11.00K derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | $50.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-06-30 | -$11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $50.00K derived: sum of 3 quarters · filed 2026-05-12 | $50.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-03-31 | $11.00K 10-Q · filed 2026-05-12 | $61.00K derived: sum of 2 quarters · filed 2026-05-12 | $61.00K derived: sum of 3 quarters · filed 2026-05-12 | $61.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $50.00K derived: sum of 2 quarters · filed 2026-03-04 | $50.00K derived: sum of 3 quarters · filed 2026-03-04 | $70.00K 10-K · filed 2026-03-04 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $20.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $20.00K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $20.00K 10-Q · filed 2025-05-08 | |||
| 2022-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $134.00K 10-K · filed 2023-03-23 | ||
| 2022-09-30 | $136.00K 10-Q · filed 2023-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |